vadimezan: Clinical Trials

4 trials of vadimezan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 withdrawn. 4 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 3, Withdrawn 1
Phase 11Completed 1

Follow vadimezan: new trials by email Literature Review of vadimezan trials Research Report on vadimezan

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
Docetaxel, ASA404 - Urothelial Carcinoma
Phase 2WithdrawnHoosier Cancer Research Network2010-06-012015-08-19
Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer
carboplatin, paclitaxel, vadimezan - Lung Cancer
Phase 2CompletedSwiss Cancer Institute172010-01-012013-04-10
Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
AS1404 (DMXAA) - Prostate Cancer
Phase 2CompletedAntisoma Research702005-05-012009-01-30
Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
DMXAA in combination with carboplatin and paclitaxel - Non-Small Cell Lung Cancer
Phase 1 / Phase 2CompletedAntisoma Research1052004-09-012009-01-30

Conditions studied

Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Transitional Cell (1)  ·  Lung Neoplasms (1)  ·  Prostatic Neoplasms (1)

Sponsors

Antisoma Research (2)  ·  Hoosier Cancer Research Network (1)  ·  Swiss Cancer Institute (1)

Countries

Switzerland (1)  ·  United States (1)

Top investigators

Mark McKeage (1)  ·  Martin Frueh, MD (1)  ·  Matthew Galsky, M.D. (1)  ·  Miklos Pless, MD (1)  ·  Oliver Gautschi, MD (1)  ·  Roberto Pili, MD (1)

Results publications

PMID 17356709, PMID 22263047, PMID 22633220